NO20004917L - Farmasøytika for avbildning av angiogene mangler - Google Patents

Farmasøytika for avbildning av angiogene mangler

Info

Publication number
NO20004917L
NO20004917L NO20004917A NO20004917A NO20004917L NO 20004917 L NO20004917 L NO 20004917L NO 20004917 A NO20004917 A NO 20004917A NO 20004917 A NO20004917 A NO 20004917A NO 20004917 L NO20004917 L NO 20004917L
Authority
NO
Norway
Prior art keywords
pharmaceuticals
deficiencies
imaging angiogenic
angiogenic
imaging
Prior art date
Application number
NO20004917A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004917D0 (no
Inventor
Miland Rajopadhye
D Scott Edwards
Thomas David Harris
Stuart J Heminway
Shuang Liu
Prahlad R Singh
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO20004917D0 publication Critical patent/NO20004917D0/no
Publication of NO20004917L publication Critical patent/NO20004917L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20004917A 1998-03-31 2000-09-29 Farmasøytika for avbildning av angiogene mangler NO20004917L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8015098P 1998-03-31 1998-03-31
US11271598P 1998-12-18 1998-12-18
PCT/US1999/006826 WO1999058162A2 (en) 1998-03-31 1999-03-29 Pharmaceuticals for the imaging of angiogenic disorders

Publications (2)

Publication Number Publication Date
NO20004917D0 NO20004917D0 (no) 2000-09-29
NO20004917L true NO20004917L (no) 2000-11-02

Family

ID=26763137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004917A NO20004917L (no) 1998-03-31 2000-09-29 Farmasøytika for avbildning av angiogene mangler

Country Status (20)

Country Link
US (2) US20020001566A1 (de)
EP (1) EP1068224B1 (de)
JP (1) JP4487019B2 (de)
KR (1) KR20010042288A (de)
CN (1) CN1295578A (de)
AR (1) AR020586A1 (de)
AT (1) ATE295369T1 (de)
AU (1) AU5541799A (de)
BR (1) BR9909420A (de)
CA (1) CA2324555A1 (de)
DE (1) DE69925262T2 (de)
EA (1) EA200001007A1 (de)
EE (1) EE200000574A (de)
ES (1) ES2241313T3 (de)
HU (1) HUP0101468A2 (de)
IL (1) IL138093A0 (de)
NO (1) NO20004917L (de)
PL (1) PL343804A1 (de)
SK (1) SK13952000A3 (de)
WO (1) WO1999058162A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AU5996201A (en) * 2000-05-08 2001-11-20 Interuniversitair Micro-Elektronica Centrum Microphysiometer
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
EP2279757A3 (de) 2000-06-02 2011-08-03 Bracco Suisse SA Arzneimitteln zum Targeting von Endothelzellen
JP2005538030A (ja) * 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
WO2001098294A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
AU2002218751A1 (en) * 2000-07-06 2002-01-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
EP1337278A2 (de) * 2000-11-27 2003-08-27 Bristol-Myers Squibb Medical Imaging, Inc. Gleichzeitiges imaging der kardialen perfusion und eines auf den vitronektin rezeptor zielgerichteten agens
US7271180B2 (en) * 2001-01-23 2007-09-18 Wyeth 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
ATE427125T1 (de) 2001-04-23 2009-04-15 Mallinckrodt Inc Tc und re markierte radioaktive glycosylierte octreotid-derivate
AU2002331042B2 (en) * 2001-08-08 2007-10-25 Bristol-Myers Squibb Pharma Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
NZ534500A (en) * 2002-01-24 2007-07-27 Barnes Jewish Hospital Nanoparticle-based emulsions specifically targeted to integrins
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7985402B2 (en) 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
WO2003074005A2 (en) * 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP2009676B8 (de) * 2002-05-08 2012-11-21 Phoseon Technology, Inc. Halbleitermaterial-Prüfsystem
US6961607B2 (en) * 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
AU2003265898A1 (en) * 2002-09-05 2004-03-29 Genentech, Inc. Infusion catheter having an integrated doppler transducer
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
EP1539804B1 (de) * 2002-09-19 2007-01-03 Centre National De La Recherche Scientifique (Cnrs) Synthese und charakterisierung neuer systeme zum hinführen und zur vektorisierung von molekülen von therapeutischem interesse zu targetzellen
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
US20050214859A1 (en) 2003-03-03 2005-09-29 Dyax Corp. Peptides that specifically bind HGF receptor (cMet) and uses thereof
WO2004100996A1 (en) * 2003-05-12 2004-11-25 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist compounds and their use in the preparation of radiopharmaceuticals
EP1651276A4 (de) * 2003-08-08 2009-05-06 Barnes Jewish Hospital Emulsionspartikel für die abbildung und therapie und verwendungsverfahren dafür
WO2005016387A2 (en) * 2003-08-12 2005-02-24 University Of Iowa Research Foundation Dna-dependent mri contrast agents
CA2559889A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
EP1720887B1 (de) * 2004-02-23 2008-04-02 Dow Gloval Technologies Inc. Klebstoff auf wasserbasis zum kleben von substraten mit niedriger oberflächenenergie
US7504088B2 (en) 2004-06-09 2009-03-17 Kereos, Inc. Lipophilic derivatives of chelate monoamides
ATE359496T1 (de) * 2004-07-02 2007-05-15 Vivactis Nv Messung der wärme erzeugt durch einen chemischen oder biologischen prozess.
WO2006094725A1 (en) * 2005-03-10 2006-09-14 Bayer Schering Pharma Aktiengesellschaft Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
JP2008540339A (ja) * 2005-04-29 2008-11-20 ワイス Nogoレセプター機能モチーフおよびそれに関するペプチド模倣物、ならびにそれらを使用する方法
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
US20070140973A1 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging
CA2650574A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
US20080138288A1 (en) * 2006-09-29 2008-06-12 Washington University Combinations for treatment of neovasculature
EP2107887A1 (de) * 2006-12-08 2009-10-14 Molecular Image Inc. Verfahren zur diagnose und überwachung von neurologischen erkrankungen mit magnetresonanz-verfahren
US8194963B2 (en) * 2008-03-10 2012-06-05 Siemens Medical Solutions Usa, Inc. Efficient estimator of pharmacokinetic parameters in breast MRI
US8110402B2 (en) 2008-05-13 2012-02-07 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
CN101659694B (zh) * 2009-05-06 2012-12-12 河北科技大学 抗肿瘤环五肽化合物及其制备方法
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
EP2979077A4 (de) * 2013-03-27 2017-05-03 Theranos, Inc. Verarbeitung biologischer proben
EP2983721B2 (de) * 2013-04-12 2021-01-20 Evox Therapeutics Limited Vesikel zur abgabe von therapeutika
DE102013113156A1 (de) * 2013-11-28 2015-05-28 Freie Universität Berlin Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
KR102548998B1 (ko) * 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물
US12377166B2 (en) * 2021-08-26 2025-08-05 University Of Washington Iron oxide nanoparticle for targeted chemo-immunotherapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
EP0086627B1 (de) 1982-02-12 1985-08-28 Unitika Ltd. Antikrebsmittel
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue
CA2002860A1 (en) 1988-11-14 1990-05-14 Michael A. Gimbrone Antibodies specific for elam-1 and the use thereof
US5376356A (en) 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
IL112768A (en) 1989-04-10 1998-06-15 Oncogen Pharmaceutical compositions containing oncostatin m for inhibiting angiogenesis
US5395609A (en) 1989-06-19 1995-03-07 Antisoma Limited Synthetic peptides for use in tumor detection
DK0436005T3 (da) 1989-07-20 1995-07-03 Sandoz Ltd Mærkede polypeptidderivater
IN172208B (de) 1990-04-02 1993-05-01 Sint Sa
WO1993008210A1 (en) 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
EP0627940B1 (de) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Verwendung von Immunokonjugate zur Diagnose und/oder Therapie der vaskularisierten Tumoren
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
DE4301871A1 (de) 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5744120A (en) 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
DE4311023C2 (de) 1993-03-31 1996-05-02 Diagnostikforschung Inst Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel
EP0710228B1 (de) 1993-07-19 1998-01-21 Resolution Pharmaceuticals Inc. Hydrazine mit einer n3s konfiguration als radionukleide chelatoren
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0762882A4 (de) 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin-rezeptor-antagonisten
CA2194369C (en) 1994-07-11 2004-08-31 Philip E. Thorpe Methods and compositions for the specific coagulation of vasculature
RU2196769C2 (ru) 1995-08-30 2003-01-20 Джи. Ди. Сирл Энд Ко. Производные аминобензойной кислоты, фармацевтическая композиция
DE19536785A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope
DE19536781A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope
US5910300A (en) * 1995-11-01 1999-06-08 Bracco Research S.A. Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds
CZ144798A3 (cs) 1995-11-14 1998-10-14 The Du Pont Merck Pharmaceutical Company Nové makrocyklické sloučeniny jako metaloproteinázové inhibitory
US6331285B1 (en) * 1996-06-05 2001-12-18 Palatin Technologies, Inc. Structurally determined cyclic metallo-constructs and applications
ZA978758B (en) * 1996-10-02 1999-03-30 Du Pont Merck Pharma Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998016256A1 (en) * 1996-10-16 1998-04-23 The Burnham Institute Magnetic resonance imaging of thrombi
ES2206689T3 (es) 1996-10-28 2004-05-16 Amersham Health As Agentes de contraste.
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE19725368A1 (de) * 1997-06-16 1998-12-17 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren
AU9477398A (en) * 1997-09-10 1999-03-29 Burnham Institute, The Methods of identifying molecules that home to angiogenic vasculature in tumors
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists

Also Published As

Publication number Publication date
JP4487019B2 (ja) 2010-06-23
DE69925262T2 (de) 2006-02-23
KR20010042288A (ko) 2001-05-25
CA2324555A1 (en) 1999-11-18
US6322770B1 (en) 2001-11-27
IL138093A0 (en) 2001-10-31
ATE295369T1 (de) 2005-05-15
BR9909420A (pt) 2001-09-25
EE200000574A (et) 2002-10-15
PL343804A1 (en) 2001-09-10
JP2002514611A (ja) 2002-05-21
AR020586A1 (es) 2002-05-22
SK13952000A3 (sk) 2001-12-03
US20020001566A1 (en) 2002-01-03
HUP0101468A2 (hu) 2001-08-28
NO20004917D0 (no) 2000-09-29
WO1999058162A3 (en) 2000-04-06
EP1068224B1 (de) 2005-05-11
EP1068224A2 (de) 2001-01-17
DE69925262D1 (de) 2005-06-16
EA200001007A1 (ru) 2001-04-23
ES2241313T3 (es) 2005-10-16
CN1295578A (zh) 2001-05-16
AU5541799A (en) 1999-11-29
WO1999058162A2 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
NO20004917L (no) Farmasøytika for avbildning av angiogene mangler
DE69837480D1 (de) Dynamische echtzeit-bildrekonstruktion
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
DE69926878D1 (de) Optoakustisches bildgebungssystem
DE69941532D1 (de) Bildaufnahmesystem
DE60038155D1 (de) Röntgenbildsystem
DK1011413T3 (da) Speculum
NO20010046L (no) Dolastatin-15-derivater
DE69928765D1 (de) Inspektionssystem
NO20000231D0 (no) Dolastatin-15-derivater
DK1466615T3 (da) Farmaceutisk præparat
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
DE69807568D1 (de) Kombiniertes Bilderzeugungsgerät
DE69715175D1 (de) Bilderzeugung
DE69906880D1 (de) Bilderzeugungsverfahren
DE69937133D1 (de) Tomografische Abtastseinrichtung
NO20010089D0 (no) Farmasöytisk levotyroksinpreparat
NO983828D0 (no) Kontrastmiddel
DE69926012D1 (de) Arzneizubereitungen
DE60017700D1 (de) Bildgebungsverfahren
ATE269337T1 (de) Trizyclische delta3-pyridine als arzneimittel
NO20016430D0 (no) Farmasöytisk kompleks
DE69906934D1 (de) Arzneizubereitungen
DE59804561D1 (de) Lippenrollvorrichtung
FI991137L (fi) Laite ja järjestely oftalmoskopiaa varten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application